CD8+ T cells are associated with tumor immune recognition and destruction (Sokol et al., 2015), and the activation of CD8+ T cells is increased via dendritic cells (Ziegler et al., 2018), which can be included in immunotherapy against cancer. This evidence concerns the gene CD8A and cancer.